黄金城集团

至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

An engineered bispecific human monoclonal antibody against SARS-CoV-2

Nat Immunol. 2022-02; 
Zhaohui Li, Shihua Li, Gen Zhang, Weiyu Peng, Zhen Chang, Xue Zhang, Zheng Fan, Yan Chai, Feiran Wang, Xin Zhao, Dedong Li, Rong Zhang, Zhanlong He, Weiwei Zou, Ke Xu, Wenwen Lei, Peipei Liu, Junfeng Hao, Jingjing Zhang, Litao Sun, Guizhen Wu, Shuguang Tan, George Fu Gao, Feng Gao, Yan Wu
Products/Services Used Details Operation
Stable Cell Lines … CD32A H131-CHOK1 cells (5 × 10 5 cells per milliliter) (GenScript, M00598) were seeded into 96-well plates. An equal volume of SARS-CoV-2 pseudovirus (1.3 × 10 4 TCID 50 per … Get A Quote

摘要

The global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic requires effective therapies against coronavirus disease 2019 (COVID-19), and neutralizing antibodies are a promising therapy. A noncompeting pair of human neutralizing antibodies (B38 and H4) blocking SARS-CoV-2 binding to its receptor, ACE2, have been described previously. Here, we develop bsAb15, a bispecific monoclonal antibody (bsAb) based on B38 and H4. bsAb15 has greater neutralizing efficiency than these parental antibodies, results in less selective pressure and retains neutralizing ability to most SARS-CoV-2 variants of concern (with more potent neutralizing activity against the Delta variant). We also selected for escape... More

关键词